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BACKGROUND
The management of patients with ovarian cancer is a complex and
evolving field. Optimal results from therapy are obtained when
patients with ovarian cancer are treated by specialist multi-
disciplinary teams (Junor et al, 1994).
The earliest stages of ovarian cancer can be treated by surgery
alone with excellent results.
The majority of women with ovarian cancer have advanced
disease at presentation and require chemotherapy as well as
surgery to improve their quality of life and increase survival.
DATA FROM RANDOMIZED TRIALS
A large meta-analysis and previous consensus statements have
established that standard chemotherapy should include a platinum
compound (Advanced Ovarian Cancer Trialists Group, 1991;
Allen et al, 1993; National Institute of Health, 1994).
Randomized trials performed before the introduction of pacli-
taxel show that carboplatin and cisplatin are equally effective in
terms of long-term survival (Advanced Ovarian Cancer Trialists
Group, 1991).
Before the introduction of paclitaxel, there had been contro-
versy surrounding the use of platinum-based combination
chemotherapy as opposed to single-agent platinum treatment. A
meta-analysis of randomized trials suggested a small advantage
for platinum combined with other drugs. However, early data from
a recent very large randomized trial suggest no benefit for a three-
drug (non-paclitaxel-containing) platinum-based regimen over
single-agent carboplatin (Advanced Ovarian Cancer Trialists
Group, 1991; Torri, 1996).
Increasing the amount of treatment by more frequent dosing,
more cycles of treatment, intraperitoneal delivery of chemo-
therapy or high-dose consolidation therapy are all areas of current
research. As yet, no conclusive data exist to suggest that such
approaches confer a survival benefit.
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Two large independent studies (totalling over 1000 patients)
have demonstrated that the combination of cisplatin and paclitaxel
confers a highly statistically significant survival advantage
compared with a standard platinum-based combination (cisplatin-
cyclophosphamide). The survival benefit is approximately 1 year
(Table 1). This represents the largest step forward in the drug treat-
ment of ovarian cancer since the introduction of platinum itself
(McGuire et al, 1996; Stuart et al, 1998).
In a third randomized study, the paclitaxel-cisplatin combina-
tion was compared with either drug given alone (Muggia et al,
1997). This showed no significant survival advantage for patients
randomized to the combination arm. However, cross-over between
treatment arms occurred at an early stage in many patients and, as
the trial progressed, the majority of patients received both drugs. It
is therefore difficult to interpret this trial, and the results do not
negate the data of McGuire et al (1996) and Stuart et al (1998).
All the current data showing that patients with ovarian cancer
obtain a survival advantage from being treated with platinum-
paclitaxel are based on regimens that use cisplatin. There are
extensive data from the pre-taxane era that indicate that cisplatin
and carboplatin are equally effective (Advanced Ovarian Cancer
Trialists Group, 1991). Carboplatin-paclitaxel combinations have
been compared with cisplatin-paclitaxel combinations in three
separate trials (Neijt et al, 1997; du Bois et al, 1998; Gynecologic
Oncology Group, 1998), and early data from two of these trials
suggest that carboplatin combinations are better tolerated in
terms of neurotoxicity and are equally effective in terms of
response rates and progression-free survival (Neijt et al, 1997;
du Bois et al, 1998).
There are no overall survival data as yet comparing the two plat-
inum analogues when given in combination with paclitaxel.
However, data on overall survival from these recently completed
trials aimed at establishing the role of carboplatin in combination
with paclitaxel will become available over the next 1-2 years
(Neijt et al, 1997; du Bois et al, 1998; Gynecologic Oncology
Group, 1998).
Patients who relapse after first-line treatment with platinum-
based chemotherapy may respond to a number of drugs. The
response rate to second-line treatment depends on the length of the
initial remission (Blackledge et al, 1989; Gore et al, 1990;
Markman et al, 1991).
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Table 1 Survival data from the two randomized studies of cisplatin-cyclophosphamide (CC) versus cisplatin-paclitaxel (CP)
n Median survival (months) Relative risk P-value
CC CP Cis-paclit
McGuire et al (1996) 386 24 38 0.6 <0.001
(0.5-0.8)
Stuart et al (1998) 668 25 35 0.71 0.003
(0.57-0.87)
Cumulative data 1054 - - 0.66 <0.000001
(0.56-0.77)
Trials have shown that one in four or five patients will respond
to paclitaxel at relapse but the duration of response is short
(median 6-9 months from the start of treatment for relapse) and
none of these patients are cured (Trimble et al, 1993; Aravintinos
et al, 1994; Athanassiou et al, 1994; Eisenhauer et al, 1994;
Markman et al, 1994; Seewaldt et al, 1994; Thigpen et al, 1994;
Uziely et al, 1994; Gore et al, 1995).
RECOMMENDATIONS
Patients with ovarian cancer should be managed in joint clinics by
specialist multidisciplinary teams.
Standard chemotherapy for patients with ovarian cancer should
include a platinum compound, and in general the preferred
analogue is carboplatin.
Six cycles of treatment should usually be given; other options,
such as prolonged treatment, high-dose regimens, or intraperi-
toneal chemotherapy, should only be administered within the
context of clinical trials.
Treatment with single-agent carboplatin represents a reasonable
option in certain situations, e.g. the frail and elderly or those for
whom alopecia is unacceptable.
For the majority of women with ovarian cancer, the recom-
mended chemotherapy should comprise a combination of pacli-
taxel with a platinum compound. On current evidence, the
platinum compound used may be either cisplatin or carboplatin.
There are no data that justify delaying the use of paclitaxel until
relapse, including those results obtained in the randomized study
of Muggia et al (1997).
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